Anti-BCMA antibody having high affinity for BCMA and pharmaceutical composition for treatment of cancer, comprising same
AssigneesMogam Institute for Biomedical Research, The Green Cross Corporation, Dana-Farber Cancer Institute, Inc.
InventorsHye-Ji Choi, Jae-Chan Park, Hyung-Kwon Lim
Life of this patent
Estimating the term…
Abstract
Provided according to an embodiment of the present invention is an antibody that binds specifically to B-cell maturation antigen (BCMA) and comprises a heavy chain variable domain (VH domain) composed of a sequence having a homology of 80% or higher with any one of the amino acid sequences of SEQ ID NOS: 1 to 20, or a fragment thereof.
Claims27
An antibody or a fragment thereof which specifically binds to B-cell maturation antigen (BCMA), said antibody or fragment thereof comprising:
- a heavy chain variable domain (VH domain) comprising the amino acid sequence of any one of SEQ ID NOs:
- 1, 3 to 18, and 20.
An antibody or a fragment thereof, which specifically binds to B-cell maturation antigen (BCMA), comprising:
- VH-CDR1 comprising the amino acid sequence of SEQ ID NO:
- 21 or 27;
- VH-CDR2 comprising the amino acid sequence of SEQ ID NO:
- 22 or 28;
- and
- VH-CDR3 comprising the amino acid sequence of SEQ ID NO:
- 23, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, or 48.
An antibody or a fragment thereof, which specifically binds to B-cell maturation antigen (BCMA), comprising:
- VH-CDR1 comprising the amino acid sequence of SEQ ID NO:
- 21, VH-CDR2 comprising the amino acid sequence of SEQ ID NO:
- 22, and VH-CDR3 comprising the amino acid sequence of SEQ ID NO:
- 23, or
- VH-CDR1 comprising the amino acid sequence of SEQ ID NO:
- 27, VH-CDR2 comprising the amino acid sequence of SEQ ID NO:
- 28, and VH-CDR3 comprising the amino acid sequence of SEQ ID NO:
- 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, or 48.
Dependencies are inferred from the claim text.